10-Q · May 8, 2026
OraSure Technologies reported its Q1 2026 results with total revenues of $27.9 million, reflecting a 7% decline year-over-year. The company suffered a wider diluted EPS loss of -$0.24 compared to -$0.21 in Q1 2025,…
Earnings analysis · 10-Q
OSUR earnings analysis
Filed August 7, 2026 · Our reading of the company's report
The latest report
OraSure's Q2 2026 revenue increased to $30.639 million from $28 million in Q1, exceeding the prior $28.0 million-$30.0 million Q2 outlook, while diluted EPS improved from a negative $0.32 to a negative $0.20. The filing…
Read full summary
OraSure's Q2 2026 revenue increased to $30.639 million from $28 million in Q1, exceeding the prior $28.0 million-$30.0 million Q2 outlook, while diluted EPS improved from a negative $0.32 to a negative $0.20. The filing does not provide updated quantitative guidance, segment results, margin data, balance-sheet data, or cash-flow data in the supplied extract. Ongoing losses, share repurchases, and the NowDiagnostics litigation remain important investor considerations, although management reported effective disclosure controls and no material risk-factor changes.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.2
What stood out
-
Revenue Rebounded Sequentially
Revenue was $30.639 million, approximately 9% above the prior quarter's $28 million and above the prior Q2 outlook range of $28.0 million to $30.0 million.
-
EPS Loss Narrowed
Diluted EPS improved to a loss of $0.20 from a loss of $0.32 in Q1 2026, although the result was below the $0.18 loss consensus estimate.
-
Continued Share Repurchases
The company repurchased 646,798 shares during the quarter under its repurchase program, with $17,960,005 remaining available at June 30, 2026.
-
Controls Remained Effective
Management concluded that disclosure controls were effective as of June 30, 2026, and reported no material change in internal control over financial reporting during the quarter.
-
Repurchase Authorization Remains
The company has a $40.0 million share repurchase authorization effective March 21, 2025, providing continuing capital-allocation flexibility.
-
Trade-Secret Litigation Advances
The NowDiagnostics preliminary injunction remains in place, and trial is scheduled for January 17, 2027, preserving a potential avenue to protect the company's proprietary information.
What to watch
-
Persistent Operating Losses
The company reported diluted EPS of negative $0.20, a loss that was $0.02 worse than the negative $0.18 consensus estimate, indicating continuing earnings pressure despite sequential improvement.
-
Capital Allocation and Liquidity
The company repurchased 646,798 shares during the quarter while retaining $17,960,005 of authorization, which could compete with liquidity needs while the company remains loss-making.
-
Pending Trade-Secret Litigation
The NowDiagnostics dispute remains unresolved; a preliminary injunction is still in place and trial is scheduled for January 17, 2027, creating ongoing legal expense and execution uncertainty.
-
Risk Disclosures Unchanged
The 10-Q states that there were no material changes to the risk factors in the December 31, 2025 Form 10-K filed March 9, 2026; therefore, the filing does not identify mitigation of the previously disclosed risks.
Management's outlook
The 10-Q does not provide new quantitative revenue or EPS guidance. The prior Q2 revenue outlook was $28.0 million to $30.0 million; current-quarter revenue was $30.639 million.
Earlier filings 4
10-K · March 9, 2026
OraSure (OTI) describes a two-pronged strategy of diagnostics products and sample management solutions, pursuing new regulatory clearances and M&A to diversify product offerings (acquired BioMedomics in November 2025).…
10-Q · August 6, 2025
OraSure reported Q2 2025 net revenue of $31.24M, down sharply from $54.34M in Q2 2024 but slightly above Q1 2025. Gross margin was 42.1% while the company reported an operating loss of $18.03M and GAAP net loss of…
10-Q · August 6, 2024
OraSure reported Q2 2024 net revenue of $54.335 million and a small GAAP net loss of $0.615 million (diluted EPS $(0.01)). Revenue was essentially flat sequentially (+$0.203 million vs Q1 2024) but down materially…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.